NRx Pharmaceuticals heads into its May 18 earnings call with short sellers aggressively rebuilding positions and the stock simultaneously pushing higher — a tension that makes this week's setup unusually charged.
Short interest has nearly doubled in under a month. SI % FF climbed from roughly 8% of free float in late April to 17% by May 14, a 43% jump in a single week and a near-doubling over 30 days. That is not incremental repositioning — it's a material conviction bet against a $3.28 stock already up 31% over the past month and 6.5% in the past week alone. The borrow market reflects the pressure: cost to borrow edged back up to 9.0% after briefly retreating mid-week, and availability has tightened meaningfully with the lending pool increasingly stretched. The ORTEX short score of 76.9 ranks in the bottom 5th percentile of the universe on short score — an extreme reading that reflects both the pace of short accumulation and the tightness of borrow conditions. Days to cover have extended to nearly seven sessions, meaning any sustained buying could force a painful unwind.
Options traders are not reading from the same script. The put/call ratio of 0.18 is actually slightly below its 20-day average of 0.16 and nowhere near the defensive extreme — the z-score is a benign 0.43. The 52-week PCR high is 0.53, hit back in April when the stock was much weaker. Right now, the options market looks relatively sanguine: call-heavy positioning and no sign of the kind of put accumulation you'd expect from a market genuinely bracing for a down-move. That divergence — aggressive short-selling paired with relaxed options hedging — is the central tension heading into Monday's event.
The Street is uniformly bullish, though the names involved are small-cap specialists rather than Wall Street bellwethers. All five covering analysts carry Buy ratings with a mean price target around $40, implying upside well above the current price. Ascendiant Capital nudged its target up to $49 in late April. Targets range from $25 (BTIG) to $49, reflecting the wide dispersion in how analysts value the regulatory pathway. The bull case rests squarely on NRx's NRX-100/101 ketamine/D-cycloserine regimen for bipolar depression with acute suicidal ideation — the company is targeting a US approval in Summer 2026, and proponents argue a ketamine supply shortage creates a commercial opening. Bears counter with the standard small-pharma arguments: approval uncertainty, potential competition, and limited cash runway. EPS momentum reads in the 2nd percentile over 30 days, and the stock is pre-revenue by any practical measure. Some historical analyst data may reflect limited coverage depth for a micro-cap name.
The earnings history from March offers context without comfort. When NRx reported results on March 24, the stock jumped 36% on the day and added another 20% over the five-day period — a violent upside reaction. That move occurred when short interest was roughly half its current level. The setup this time is different: a larger short base heading in, a stock that has already run hard into the event, and a borrow market under increasing strain. The FINRA-reported short interest of 4.4 million shares (settlement date April 30) confirmed the build was real well before this week's acceleration.
Institutional ownership is thin but notable in its composition. Anson Group holds 9.2% of shares, alongside founder Jonathan Javitt at 4.6% and several other concentrated holders. The top 26 institutional holders collectively hold a relatively small portion of the float, which contributes to the liquidity squeeze dynamic when both buyers and short-sellers are active simultaneously. Insider data is stale — the most recent disclosed trade dates to December 2024 — so there is no fresh signal there.
What to watch heading into May 18: whether the company provides any regulatory update on its Summer 2026 ketamine approval timeline, and how shorts respond to whatever the print contains — with 7 days to cover and a heavily call-skewed options market, any positive surprise could accelerate the unwind already implied by the borrow stress.
See the live data behind this article on ORTEX.
Open NRXP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
